Gaelle Jeannin1, Patrick Merle2, Henri Janicot2, Lise Thibonnier3, Fabrice Kwiatkowski4, Adel Naame5, J Baptiste Chadeyras5, Géraud Galvaing5, Aurélie Belliere6, Marc Filaire5, Pierre Verrelle7. 1. Thoracic Oncology Unit, Clermont-Ferrand University Hospital, Rue Montalembert, BP 69, 63003 Clermont-Ferrand, France. gjeannin@chu-clermontferrand.fr. 2. Thoracic Oncology Unit, Clermont-Ferrand University Hospital, 63003 Clermont-Ferrand, France; Clermont University, Université d'Auvergne, 63003 Clermont-Ferrand, France. 3. Thoracic Oncology Unit, Clermont-Ferrand University Hospital, 63003 Clermont-Ferrand, France. 4. Medical Informatic Department, Jean Perrin Anti-Cancer Center, 63011 Clermont-Ferrand, France. 5. Thoracic Surgery Unit, Jean Perrin Anti-Cancer Center, 63011 Clermont-Ferrand, France. 6. Radiotherapy Department, Jean Perrin Anti-Cancer Center, 63011 Clermont-Ferrand, France. 7. Clermont University, Université d'Auvergne, 63003 Clermont-Ferrand, France; Radiotherapy Department, Jean Perrin Anti-Cancer Center, 63011 Clermont-Ferrand, France.
Abstract
BACKGROUND: A retrospective monocentric study of consecutive patients with superior sulcus tumor non-small cell lung cancer (SS-NSCLC), treated by induction concurrent chemoradiotherapy (CRT), article management. METHODS: From 1994 to 2005, 36 patients (15 T3, 21 T4 tumors, including N2-N3 node involvement) received induction CRT with cisplatin/vinorelbine/fluorouracil combined with 44 Gy radiotherapy (5 daily 2 Gy fractions/week). After CRT completion, RECIST evaluation and operability were assessed. In resectable patients, surgery was performed one month after CRT. Patients with unresectable disease followed CRT up to 66 Gy. The median of follow-up period was 38.6 months [2-206]. RESULTS: Induction CRT was completed for 94.4% with 71% radiological objective response (OR). Sixteen patients (44%) underwent surgical resection, and pathologic complete resection was performed in 93.8%. There were 7 patients (44%) with pathologic complete response. The median disease-free survival (DFS) time was 12.9 months with DFS rates at 1 and 2 years 53.6% and 39.1% respectively. The median overall survival (OS) was 46.4 months. The OS rates at 2 and 5 years were 68.8% and 37.5% respectively with no difference between T3 and T4 tumors. In unresectable disease, the median DFS time was 8.1 months. The DFS rate at 1 year was 25.2%. The median OS was 9.1 months. The OS rates at 1 and 2 years were 45% and 16.9% respectively. Recurrences were found in 72% of patients. Brain metastasis was the most common site of recurrence. Prognostic factors for OS were the response to induction treatment, the possibility of surgery, and pathologic complete response. CONCLUSIONS: This trimodality treatment regimen confers a survival outcome in agreement with previous studies. Patients with pretreatment N3 lymph node should be included in trimodality treatment.
BACKGROUND: A retrospective monocentric study of consecutive patients with superior sulcus tumor non-small cell lung cancer (SS-NSCLC), treated by induction concurrent chemoradiotherapy (CRT), article management. METHODS: From 1994 to 2005, 36 patients (15 T3, 21 T4 tumors, including N2-N3 node involvement) received induction CRT with cisplatin/vinorelbine/fluorouracil combined with 44 Gy radiotherapy (5 daily 2 Gy fractions/week). After CRT completion, RECIST evaluation and operability were assessed. In resectable patients, surgery was performed one month after CRT. Patients with unresectable disease followed CRT up to 66 Gy. The median of follow-up period was 38.6 months [2-206]. RESULTS: Induction CRT was completed for 94.4% with 71% radiological objective response (OR). Sixteen patients (44%) underwent surgical resection, and pathologic complete resection was performed in 93.8%. There were 7 patients (44%) with pathologic complete response. The median disease-free survival (DFS) time was 12.9 months with DFS rates at 1 and 2 years 53.6% and 39.1% respectively. The median overall survival (OS) was 46.4 months. The OS rates at 2 and 5 years were 68.8% and 37.5% respectively with no difference between T3 and T4 tumors. In unresectable disease, the median DFS time was 8.1 months. The DFS rate at 1 year was 25.2%. The median OS was 9.1 months. The OS rates at 1 and 2 years were 45% and 16.9% respectively. Recurrences were found in 72% of patients. Brain metastasis was the most common site of recurrence. Prognostic factors for OS were the response to induction treatment, the possibility of surgery, and pathologic complete response. CONCLUSIONS: This trimodality treatment regimen confers a survival outcome in agreement with previous studies. Patients with pretreatment N3 lymph node should be included in trimodality treatment.
Entities:
Keywords:
Sulcus non-small cell lung cancer (Sulcus NSCLC); chemoradiotherapy (CRT); prognosis; surgery
Authors: Elizabeth George; Maria Barile; Anji Tang; Ory Wiesel; Antonio Coppolino; Andreas Giannopoulos; Steven Mentzer; Michael Jaklitsch; Andetta Hunsaker; Dimitrios Mitsouras Journal: J Surg Oncol Date: 2017-09 Impact factor: 3.454
Authors: Alessandra Buja; Michele Rivera; Anna De Polo; Eugenio di Brino; Marco Marchetti; Manuela Scioni; Giulia Pasello; Alberto Bortolami; Vincenzo Rebba; Marco Schiavon; Fiorella Calabrese; Giovanni Mandoliti; Vincenzo Baldo; PierFranco Conte Journal: Thorac Cancer Date: 2020-11-21 Impact factor: 3.500